June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|January 30, 2021
When is it not glaucoma: Masquerade syndromes
Author(s)OT Staff Reports
Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.
Advertisement
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Alvotech files first known aflibercept 8 mg biosimilar with EMA
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5